Resource Summary

Clinical Question:
For patients with non-valvular atrial fibrillation (AF)^ do the NOACs (dabigatran^ rivaroxaban^ apixaban) have advantages over warfarin?

Bottom-line:
Compared to warfarin^ NOACs offer some benefits for patients with non-valvular atrial fibrillation. The decision to use a NOAC or warfarin should be made after reviewing the patient’s previous INR stability^ kidney function and discussing the potential benefits and risks^ direct and indirect costs with the patient.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2012-9-18
Last Updated on PCR: 2017-04-01 09:38:07